PPD has nominated three new members for stockholders to consider electing to its board of directors. Vaughn Bryson worked at Eli Lilly for 32 years, rising to the positions of president and CEO.
Nominated alongside Bryson were Robert Ingram and Ralph Snyderman. Ingram is the former CEO of chairman of GlaxoWellcome and co-led the merger to form GlaxoSmithKline. Snyderman is professor of medicine at Duke University and began his career at Genentech.
Richard Johnson has joined the advisory board at Clinilabs. Johnson is a venture capital investor with the Mid Atlantic Fund and is the former CEO of Quintiles Commercialisation North America.
Clearstone Central Laboratories has promoted Nick Ayers and Odile Keller to head of business development in North America and Europe, respectively. Ayers has previously worked at MDS Pharma Services, PPD and Covance. Keller also used to work at MDS.
Julia Dishman has been appointed as manger, sales and marketing at BioProcess Technology Consultants (BPTC). Dishman last worked as an independent consultant, for BPTC and other companies, and has also held positions at Merrimack Pharmaceuticals.
Clariant Masterbatches has given Gunther Luebke responsibility for the ISO 13485 quality system and oversight of specific regulatory requirements. Earlier in his career Luebke was part of the Clariant team within the Masterbatch business unit on REACH.
David Kirk and Sandra Marticio have joined ParagonRx as commercial development directors. Marticio has previously worked at Aegis Creative and BVP Media. Kirk is a former Johnson & Johnson employee.
Aptiv Solutions has named Michael McKelvey as executive vice president and chief operating officer. Earlier in his career McKelvey worked at eResearchTechnology and Parerxel.